Please wait...


Generic Name: insulin aspart (IN su lin AS part)
Brand Name: Fiasp, NovoLOG, NovoLOG FlexPen, NovoLOG PenFill
Physician reviewed Fiasp patient information - includes Fiasp description, dosage and directions.
  • Prescription Settings

Prices and coupons of Fiasp

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Insulin is a hormone that works by lowering levels of glucose (sugar) in the blood. Fiasp is a fast-acting insulin that starts to work about 15 minutes after injection, peaks in about 1 hour, and keeps working for 2 to 4 hours. Fiasp is used to improve blood sugar control in adults and children with diabetes mellitus. Fiasp is sometimes used together with a long-acting or intermediate-acting insulin. Fiasp may also be used for purposes not listed in this medication guide. Never share an injection pen, cartridge, or syringe with another person, even if the needle has been changed. Learn more

Fiasp Side Effects

Fiasp Side Effects

Note: This document contains side effect information about insulin aspart. Some of the dosage forms listed on this page may not apply to the brand name Fiasp.

For the Consumer

Applies to insulin aspart: solution

Along with its needed effects, insulin aspart (the active ingredient contained in Fiasp) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking insulin aspart:

More common

  • Anxiety
  • behavior change similar to being drunk
  • blurred vision
  • cold sweats
  • confusion
  • depression
  • difficulty with thinking
  • dizziness or lightheadedness
  • drowsiness
  • excessive hunger
  • fast heartbeat
  • headache
  • irritability or abnormal behavior
  • nightmares
  • restless sleep
  • seizures
  • shakiness
  • slurred speech
  • tingling in the hands, feet, lips, or tongue

Less common

  • Depression of the skin at the place of injection
  • dryness of the mouth
  • fast or weak pulse
  • feeling of pressure, itching, redness, soreness, stinging, swelling, or tingling at the place of injection
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • mood or mental changes
  • muscle cramps or pain
  • nausea
  • skin rash or itching over the whole body
  • sweating
  • thickening of the skin at the place of injection
  • trouble breathing
  • unusual tiredness or weakness
  • vomiting


  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • difficulty in breathing or swallowing
  • rapid weight gain
  • redistribution or accumulation of body fat
  • swelling of the face, throat, or tongue
  • unusual weight gain or loss

Some side effects of insulin aspart may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Back pain
  • body aches or pain
  • chills
  • cough
  • diarrhea
  • ear congestion
  • fever
  • loss of voice
  • muscle aches
  • nasal congestion
  • sneezing
  • sore throat
  • stuffy or runny nose

For Healthcare Professionals

Applies to insulin aspart: injectable solution, subcutaneous solution


Adverse reactions observed have included hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.


Hypersensitivity side effects have included both local and systemic reactions. Anaphylaxis has been reported. Local reactions have presented as erythema, local edema, and pruritus at the injection site. Most minor reactions to insulin at the injection site resolve in a few days to a few weeks.

Generalized allergy to insulin may present as a whole body rash, dyspnea, wheezing, hypotension, tachycardia, or diaphoresis. In clinical trials, allergic reactions were reported in 0.7% (10/1394) patients receiving insulin aspart (the active ingredient contained in Fiasp)

Clinical trials with Fiasp(R) reported generalized hypersensitivity reactions at 0.2% (comparator 0.1%). Anaphylactic reactions were not reported. Allergic skin manifestations were reported at 1.5% (comparator 1.4%) and included eczema, rash, pruritic rash, urticaria, and dermatitis.

Very rare (less than 0.01%): Anaphylaxis

Common (1% to 10%): Allergic skin manifestations

Frequency not reported: Allergic reactions


Very common (10% or more): Hypoglycemia

Frequency not reported: Weight gain

Weight gain has been reported with insulin therapy and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.


Common (1% to 10%): Chest pain

Uncommon (0.1% to 1%): Peripheral edema

Insulin may cause sodium retention and edema, especially as metabolic control is improving.


Long-term use of insulin may cause lipodystrophy at the site of repeated injection. Lipodystrophy includes lipohypertrophy, a thickening of adipose tissue, and lipoatrophy, thinning of adipose tissue.

Common (1% to 10%): Skin disorder

Uncommon (0.1% to 1%): Urticaria, rash

Frequency not reported: Lipodystrophy including lipohypertrophy and lipoatrophy


Common (1% to 10%): Onychomycosis

Frequency not reported: Anti-insulin antibody titers

The clinical significance of the development of these antibody titers is unknown.


Uncommon (0.1% to 1%): Refraction disorder, worsening of diabetic retinopathy

Rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder and worsening of diabetic retinopathy. However, long-term glycemic control decreases the risk of diabetic retinopathy.

Nervous system

Rapid improvement in glucose control has been associated with a transitory, reversible acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk.

Very common (10% or more): Headache (up to 12%)

Common (1% to 10%): Hyporeflexia, sensory disturbance

Rare (less than 0.1%): Painful peripheral neuropathy


Common (1% to 10%): Nausea, diarrhea, abdominal pain


Common (1% to 10%): Urinary tract infection


Common (1% to 10%): Back pain


Very common (10% or more): Nasopharyngitis (23%)

Common (1% to 10%): Upper respiratory infection

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Fiasp